EQ (Equillium) FCF Margin % : -62.96% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Equillium FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Equillium's Free Cash Flow for the three months ended in Sep. 2024 was $-7.66 Mil. Equillium's Revenue for the three months ended in Sep. 2024 was $12.16 Mil. Therefore, Equillium's FCF Margin % for the quarter that ended in Sep. 2024 was -62.96%.

As of today, Equillium's current FCF Yield % is -76.14%.

The historical rank and industry rank for Equillium's FCF Margin % or its related term are showing as below:

EQ' s FCF Margin % Range Over the Past 10 Years
Min: -60.51 Med: -58.85 Max: -46.77
Current: -46.77

During the past 7 years, the highest FCF Margin % of Equillium was -46.77%. The lowest was -60.51%. And the median was -58.85%.

EQ's FCF Margin % is ranked better than
59.98% of 1022 companies
in the Biotechnology industry
Industry Median: -143.22 vs EQ: -46.77

Equillium FCF Margin % Historical Data

The historical data trend for Equillium's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium FCF Margin % Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-57.19

-60.51

Equillium Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-21.52	-61.49	-82.51	4.82	-62.96

Competitive Comparison of Equillium's FCF Margin %

For the Biotechnology subindustry, Equillium's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Equillium's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Equillium's FCF Margin % falls into.

Equillium FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Equillium's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-21.833	/	36.084
	=	-60.51 %

Equillium's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-7.657	/	12.161
	=	-62.96 %

Equillium FCF Margin % Related Terms

Thank you for viewing the detailed overview of Equillium's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (NAS:EQ) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0A4D:UK 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Executives

Jason A Keyes	officer: Chief Financial Officer	3344 NORTH TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christine Zedelmayer	officer: Sr. Vice President and COO	2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Barbara Troupin	director	C/O EQUILLIUM, INC., 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Stephen Connelly	director, officer: Chief Scientific Officer	2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Decheng Capital Management Iv (cayman), Llc	10 percent owner	P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Decheng Capital Global Life Sciences Fund Iv, L.p.	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, P.O. BOX 309, GRAND CAYMAN E9 KY1-1104
Xiangmin Cui	10 percent owner	NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000
Yu (katherine) Xu	director	P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Joel Rothman	officer: Chief Development Officer	2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Dolca Thomas	officer: Chief Medical Officer	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bala S Manian	director	1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Charles Douglas Mcdermott	director	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Krishna R Polu	officer: Chief Medical Officer	C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Sa Biocon	10 percent owner	CO BDO SA, RUE DE LAVENIR 2, DELEMONT V8 2800
Bruce D. Steel	director, officer: President, CBO	C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555